Author

M. Angelova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Organism:human· 2 Approach:microscopy & imaging analysis· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

C. Moore· 3 shared C. Swanton· 3 shared E. Colliver· 2 shared E. Mugarza· 2 shared F. van Maldegem· 2 shared J. Downward· 2 shared K. Enfield· 2 shared K. Valand· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Moore

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

M. Cole, P. Anastasiou, C. Lee, C. Moore, E. Mugarza, M. Jones, K. Valand, S. Rana, E. Colliver, M. Angelova, K. Enfield, A. Magness, A. Mullokandov, G. Kelly, T. de Gruijl, , F. van Maldegem

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

bioRxiv · Apr 11, 2024Cancer Biology

Characterisation of tumour immune microenvironment remodelling following oncogene inhibition in preclinical studies using an optimised imaging mass cytometry workflow

F. van Maldegem, K. Valand, M. Cole, H. Patel, M. Angelova, S. Rana, E. Colliver, K. Enfield, N. Bah, V. Tsang, E. Mugarza, C. Moore, P. Hobson, D. Levi, M. Molina, , J. Downward

The paper optimises an imaging mass cytometry workflow to study TME remodelling in mouse models after KRAS G12C inhibitor treatment.

bioRxiv · Feb 2, 2021Cancer Biology

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

D. R. Caswell, M. K. Mayekar, P. Gui, E. K. Law, N. I. Vokes, C. M. Ruiz, M. Dietzen, M. Angelova, C. Bailey, O. Pich, B. Bakker, W. Wu, T. J. Humpton, D. L. Kerr, W. Hill, , Argyr

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

bioRxiv · Dec 18, 2020Cancer Biology

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer

F. Correia Martins, D.-L. Couturier, I. Santiago, C. Sauer, M. Vias, M. Angelova, D. Sanders, A. Piskorz, J. Hall, K. Hosking, A. Amirthanayagam, S. Cosulich, L. Carnevalli, B. Davies, T. B. K. Watkins, , J. D. Brenton

This study shows that somatic copy number alterations in driver genes correlate with drug response in HGSOC spheroid models and clinical settings.

bioRxiv · Oct 4, 2020 · PreprintCancer Biology

Multiple roles for the ESCRT machinery in maintaining plasma membrane homeostasis

O. Schmidt, Y. Weyer, S. Sprenger, M. A. Widerin, S. Eising, V. Baumann, M. Angelova, R. Loewith, C. J. Stefan, M. W. Hess, F. Froehlich, D. Teis

This study investigates the role of ESCRT machinery in plasma membrane homeostasis using budding yeast, revealing its involvement in membrane tension regulation and sphingolipid metabolism through calcineurin/TORC2 signaling.

bioRxiv · Feb 25, 2020Cell Biology